The CDK4/6 pathway is hyperactivated in around 90% of melanoma cases [2] mainly due to the loss of the tumour suppressor p16 INK4A [3], a direct inhibitor of CDK4/6 activity. The gene discussed is CDK4; the disease is melanoma.